Author: Essential Pharma

Posted Date:

April 14, 2026

Renaissance Pharma Limited, an Essential Pharma company, secures FDA Fast Track Designation and IND clearance for Daretabart (hu1418K322A) in high-risk neuroblastoma

Essential Pharma

April 14, 2026
Essential Pharma strengthens rare disease portfolio with acquisition of Ventavis® (iloprost trometamol) for adult primary pulmonary hypertension

Essential Pharma

February 17, 2026